<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02670785</url>
  </required_header>
  <id_info>
    <org_study_id>EVC-MD-01</org_study_id>
    <nct_id>NCT02670785</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy</brief_title>
  <official_title>A Phase 2, Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate Safety and Efficacy of Three Doses of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Warner Chilcott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Warner Chilcott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will access the safety and efficacy of three doses of estradiol vaginal capsules
      in postmenopausal women with vulvovaginal atrophy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2016</start_date>
  <completion_date type="Actual">November 14, 2016</completion_date>
  <primary_completion_date type="Actual">November 14, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the percentage of vaginal superficial cells</measure>
    <time_frame>Baseline (Week 0) to Final Visit (Week 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the percentage of vaginal parabasal cells</measure>
    <time_frame>Baseline (Week 0) to Final Visit (Week 6)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in vaginal pH</measure>
    <time_frame>Baseline (Week 0) to Final Visit (Week 6)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the investigator assessment of VVA measured by scoring the vaginal health in 5 categories using a 4-point scale</measure>
    <time_frame>Baseline (Week 0) to Final Visit (Week 6)</time_frame>
    <description>Outcome was measured by using a 4-point severity scale with: None=0, Mild=1, Moderate=2, and Severe=3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subject's self-assessment of vaginal dryness reported as the most bothersome symptom</measure>
    <time_frame>Baseline (Week 0) to Final Visit (Week 6)</time_frame>
    <description>Outcome was measured by using a 4-point severity scale with: None=0, Mild=1, Moderate=2, and Severe=3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subject's self-assessment of dyspareunia reported as the most bothersome symptom</measure>
    <time_frame>Baseline (Week 0) to Final Visit (Week 6)</time_frame>
    <description>Outcome was measured by using a 4-point severity scale with: None=0, Mild=1, Moderate=2, and Severe=3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subject's self-assessment of dysuria</measure>
    <time_frame>Baseline (Week 0) to Final Visit (Week 6)</time_frame>
    <description>Outcome was measured by using a 4-point severity scale with: None=0, Mild=1, Moderate=2, and Severe=3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subject's self-assessment of vaginal and/or vulvar irritation/itching</measure>
    <time_frame>Baseline (Week 0) to Final Visit (Week 6)</time_frame>
    <description>Outcome was measured by using a 4-point severity scale with: None=0, Mild=1, Moderate=2, and Severe=3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subject's self-assessment of vaginal dryness in patients where vaginal dryness was not reported as the most bothersome symptom</measure>
    <time_frame>Baseline (Week 0) to Final Visit (Week 6)</time_frame>
    <description>Outcome was measured by using a 4-point severity scale with: None=0, Mild=1, Moderate=2, and Severe=3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subject's self-assessment of dyspareunia in patients where dyspareunia was not reported as the most bothersome symptom</measure>
    <time_frame>Baseline (Week 0) to Final Visit (Week 6)</time_frame>
    <description>Outcome was measured by using a 4-point severity scale with: None=0, Mild=1, Moderate=2, and Severe=3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-assessment by sexually active participants as to the presence or absence of vaginal bleeding</measure>
    <time_frame>Baseline (Week 0) to Final Visit (Week 6)</time_frame>
    <description>Total number of participants who were sexually active assessed if vaginal bleeding was present or absent.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">203</enrollment>
  <condition>Vulvovaginal Atrophy</condition>
  <condition>Menopause</condition>
  <condition>Dyspareunia</condition>
  <arm_group>
    <arm_group_label>Estradiol Vaginal Capsule 0.003 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estradiol Vaginal Capsule 0.01 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estradiol Vaginal Capsule 0.02 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol Vaginal Capsule (EVC)</intervention_name>
    <description>Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks</description>
    <arm_group_label>Estradiol Vaginal Capsule 0.003 mg</arm_group_label>
    <arm_group_label>Estradiol Vaginal Capsule 0.01 mg</arm_group_label>
    <arm_group_label>Estradiol Vaginal Capsule 0.02 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of vulvovaginal atrophy due to post menopause

          -  Age ≥ 40 years or if bilateral oophorectomy ≥ 35 years

          -  Moderate to severe vaginal dryness

          -  Normal breast exam; if &gt; 40 years

          -  Vaginal pH &gt; 5.0

          -  &lt; 5% superficial cells on vaginal wall cytology smear

        Exclusion Criteria:

          -  Known hypersensitivity to estrogen and/or progestin therapy

          -  Known or suspected premalignant or malignant disease

          -  Undiagnosed abnormal genital bleeding

          -  A history of or treatment for significant cardiovascular disease, congestive heart
             failure, or stroke

          -  Active or known protein C, protein S, or antithrombin deficient, or other known
             thrombophilic disorders or thromboembolic events

          -  Increased frequency/severity headaches with estrogen therapy

          -  Smokes ≥ 15 cigarettes/day
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vilma Sniukiene, MD</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Visions Clinical Research-Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Connecticut Research, LLC</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Medical Research Group, LLC</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Trials, LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fellows Research Alliance, Inc</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beyer Research</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of R. Garn Mabey, M.D.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Women's Research and Wellness Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawthorne Medical Research, Inc.</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Philadelphia, LLC</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fellows Research Alliance, Inc</name>
      <address>
        <city>Bluffton</city>
        <state>South Carolina</state>
        <zip>29910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Women's Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Women's Health, Research, Gynecology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Spokane Women's Clinic</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Dyspareunia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

